



Indian Point Energy Center  
450 Broadway, GSB  
P.O. Box 249  
Buchanan, N.Y. 10511-0249  
Tel (914) 734-6700

J. E. Pollock  
Site Vice President

NL-10-120

November 8, 2010

U.S. Nuclear Regulatory Commission  
Attn: Document Control Desk  
Mail Stop O-P1-17  
Washington, D.C. 20555-0001

**SUBJECT:** Report of Testing Errors on Fitness For Duty Blind Samples by an HHS-Certified Laboratory  
Indian Point Unit Nos. 1, 2, and 3  
Docket Nos. 50-03, 50-247, and 50-286  
License Nos. DPR-5, DPR-26 and DPR-64

Dear Sir or Madam:

Pursuant to 10 CFR 26.719(c)(1), Entergy Nuclear Operations Inc. (Entergy) hereby provides, Enclosure 1, a report of an investigation into performance testing errors by an HHS-certified laboratory. Two Fitness for Duty (FFD) blind Quality Assurance samples were incorrectly reported to the medical review officer (MRO) and Indian Point Energy Center (IPEC) as negative however one should have been reported as positive for cocaine and the other positive for opiates.

There are no new commitments identified in this letter. Should you have any questions regarding this submittal, please contact Mr. Robert Walpole, Manager, Licensing at (914) 734-6710.

Sincerely,

JEP/sp

cc: Mr. John P. Boska, Senior Project Manager, NRC NRR DORL  
Mr. William Dean, Regional Administrator, NRC Region I  
NRC Resident Inspector's Office, Indian Point 3  
Mr. Paul Eddy, New York State Public Service Commission

Enclosure: 1. Letter to Entergy dated October 13, 2010

A022  
FSME20  
NRR  
FSME

**Enclosure 1 to NL-10-120**

**LETTER TO ENTERGY DATED OCTOBER 13, 2010**

**ENTERGY NUCLEAR OPERATIONS, INC.  
INDIAN POINT NUCLEAR GENERATING UNIT NOS. 1, 2 AND 3  
DOCKET NOS. 50-03, 50-247, AND 50-286**



October 13, 2010

Kelly Pettus  
Indian Point/Entergy  
450 Broadway  
Buchanan, NY 10511

Dear Ms. Pettus:

Two specimens, which were identified by you as blind urine quality control specimens, were received at Quest Diagnostics in Norristown, Pennsylvania on September 21, 2010 with the following identification and results:

Specimen ID #	2409262	2409269
Laboratory ID	647879X	647865X
Donor ID	292-89-4241	145-96-2821
Collection Date	9/20/2010	9/20/2010
Reported	Negative	Negative
Report Date	9/21/2010	9/22/2010

Our laboratory was notified by you that neither specimen achieved the target result and we initiated an investigation.

Investigation:

- The data from the initial (screening) test was reviewed. The summary data from our chemistry analyzer was interpreted correctly. We then reviewed the data directly from the analyzer and reviewed the bar-code numbers associated with the specimens. When a portion of urine is tested, the portion ("aliquot") is placed in a bar-coded tube. Test information and results are linked between the specimen and our computer system through this assigned bar-code. Upon review of the bar-codes, we found that the bar-codes for these two sequentially tested specimens were reversed. Consequently, the correct screening data was not captured.
- Confirmation testing by GC/MS was performed on these specimens based on the correct screening data. Specimen 2409262 confirmed positive for Cocaine metabolite (628 ng/mL) and Specimen 2409269 confirmed positive for Morphine (3999 ng/ml). Corrected reports were issued 10/4/2010 and 10/5/2010 respectively.

Corrective Action:

Several corrective action steps were taken.


1. This incident was reviewed with the appropriate staff.

2. Our Standard Operating Procedures were revised on October 1, 2010. This revision places additional focus on the review of bar code sequencing on screening loads that are prepared through the same manual aliquoting process used for these two samples.
3. The bar-coded tubes have now been glued into the rack holders so that it will no longer be possible for staff to remove tubes. By permanently fixing these tubes in place, the possibility of getting tubes out of sequence is eliminated.

We regret that we failed to accurately identify these two blind quality control samples but are confident that the corrective actions taken should effectively eliminate a future recurrence of such an incident.

Should have any additional questions or concerns, please call me at (877) 642-2216 x 4502.

Sincerely,



Susan Mills  
Operations Director, Forensic Toxicology